Acute Toxicity Study of Seed-Based Polymers in Wistar Rats: Evaluation of Safety Profile
Abstract
Seed-based polymers are gaining attention in pharmaceutical formulations due to their biodegradable and biocompatible nature. The present study evaluates the acute toxicity profile of three different seed-based polymers in Wistar rats. Single oral doses (2000 mg/kg) were administered as per OECD guideline 423. The study recorded mortality, body weight changes, behavioral alterations, and biochemical parameters to assess any potential toxic effects. No mortality or significant behavioral changes were observed, confirming the safety of these polymers. Histopathological examination revealed no signs of toxicity, reinforcing their biocompatibility. The findings suggest the potential safe use of these polymers in drug delivery applications and highlight the need for further studies on their long-term safety.
Downloads
References
2. Njan AA, Atolani O, Olorundare OE, et al. Chronic toxicological evaluation and reversibility studies of Moringa oleifera ethanolic seed extract in Wistar rats. Trop J Health Sci. 2018;25(1):15-22.
3. Dibua MUE, Garba DE, Elechenu EC, et al. Assessment of acute toxicity, LD50 and histopathological evaluation of Nigella sativa and Moringa oleifera seed extracts in Wistar rats. Trop J Nat Prod Res. 2022;6(11):1840-3.
4. Reddy N, Yang Y. Properties and potential applications of natural cellulose fibers from the bark of cotton stalks. Bioresour Technol. 2009;100(14):3563-9.
5. Sahoo S, Sasmal D, Banji D. Evaluation of Benincasa hispida seed mucilage as mucoadhesive agent. Int J PharmTech Res. 2010;2(1):592-8.
6. Kumar R, Patil MB, Patil SR, Paschapur MS. Evaluation of Abelmoschus esculentus mucilage as suspending agent in paracetamol suspension. Int J PharmTech Res. 2009;1(3):658-65.
7. Goyal R, Sharma P, Sharma S, et al. Evaluation of Moringa oleifera seed extract for antimicrobial activity: A review. J Phytol Phytopharmacol. 2010;2(1):1-5.
8. Kumar GP, Rajeshwarrao P. Nonionic surfactant vesicular systems for effective drug delivery—an overview. Acta Pharm Sin B. 2011;1(4):208-19.
9. Kumar A, Rao KM, Han SS. Application of xanthan gum as polysaccharide in tissue engineering: A review. Carbohydr Polym. 2018;180:128-44.
10. Mishra A, Malhotra AV. Tamarind xyloglucan: A polysaccharide with versatile application potential. J Mater Chem. 2009;19(45):8528-36.
11. Shirwaikar A, Prabu SL, Kumar GA. Herbal excipients in novel drug delivery systems. Indian J Pharm Sci. 2008;70(4):415-22.
12. Gandhi A, Paul A, Sen SO, Sen KK. Studies on thermoresponsive polymers: Phase behaviour, drug delivery and biomedical applications. Asian J Pharm Sci. 2015;10(2):99-107.
13. Mali AD, Dias RJ, Havaldar VD. Evaluation of Cassia tora mucilage as tablet binder. Int J PharmTech Res. 2010;2(2):1367-70.
14. Kumar R, Patil MB, Patil SR, Paschapur MS. Isolation and evaluation of disintegrant properties of fenugreek seed mucilage. Int J PharmTech Res. 2009;1(4):982-96.
15. U.S. Food and Drug Administration. Inactive Ingredient Database [Internet]. Silver Spring (MD): FDA; 2023 [cited 2025 Apr 21]. Available from:
https://www.fda.gov/drugs/drug-approvals-and-databases/inactive-ingredient-database
16. European Medicines Agency. Guideline on Excipients in the Dossier for Application for Marketing Authorisation of a Medicinal Product. Report No.: EMEA/CHMP/QWP/ 396951/2006 [Internet]. London: EMA; 2007 Jun 19 [cited 2025 Apr 21]. Available from:
https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-excipients-dossier-application-marketing-authorisation-medicinal-product-revision-2_en.pdf
17. Rowe RC, Sheskey PJ, Quinn ME, editors. Handbook of Pharmaceutical Excipients. 7th ed. London: Pharmaceutical Press; 2012.
18. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH Harmonised Tripartite Guideline: Impurities in New Drug Products Q3B(R2). [Internet]. Geneva: ICH; 2006 Jun 02 [cited 2025 Apr 21]. Available from:
https://database.ich.org/sites/default/files/Q3B%28R2%29%20Guideline.pdf
19. Singh A, Sharma PK, Malviya R. Extraction and characterization of Moringa oleifera gum as pharmaceutical excipient. Polim Med. 2014;44(1):39-44.
20. Kumar R, Patil MB, Patil SR, Paschapur MS. Evaluation of Abelmoschus esculentus mucilage as suspending agent in paracetamol suspension. Int J PharmTech Res. 2009;1(3):658-65.
21. Singh S, Bothara SB, Singh V. Evaluation of Lepidium sativum seed mucilage as rate controlling matrix for sustained release of diclofenac sodium. Int J PharmTech Res. 2010;2(1):1350-7.
22. Goyal R, Sharma P, Sharma S, et al. Evaluation of Moringa oleifera seed extract for antimicrobial activity: A review. J Phytol Phytopharmacol. 2010;2(1):1-5.
23. Kumar GP, Rajeshwarrao P. Nonionic surfactant vesicular systems for effective drug delivery-an overview. Acta Pharm Sin B. 2011;1(4):208-19.
24. Kumar A, Rao KM, Han SS. Application of xanthan gum as polysaccharide in tissue engineering: A review. Carbohydr Polym. 2018;180:128-44.
25. Parasuraman S. Toxicological screening. J Pharmacol Pharmacother. 2011;2(2):74-9.
26. Turner PV, Brabb T, Pekow C, Vasbinder MA. Administration of substances to laboratory animals: routes of administration and factors to consider. J Am Assoc Lab Anim Sci. 2011;50(5):600-7.
27. Bais S, Singh GS, Sharma R. Acute and subacute toxicity study of root aqueous extract of Berberis aristata DC in rodents. J Adv Pharm Technol Res. 2012;3(2):101-10.
28. Olson H, Betton G, Robinson D, et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol. 2000;32(1):56-67.
29. Fischer AH, Jacobson KA, Rose J, Zeller R. Hematoxylin and eosin staining of tissue and cell sections. CSH Protoc. 2008;2008:pdb.prot4986.
30. Suvarna SK, Layton C, Bancroft JD. Bancroft's Theory and Practice of Histological Techniques. 7th ed. Churchill Livingstone; 2012.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The International Journal of Drug Regulatory affairs require a formal written transfer of copyright from the author(s) for each article published. We therefore ask you to complete and return this form, retaining a copy for your records. Your cooperation is essential and appreciated. Any delay will result in a delay in publication.
I/we have read and agree with the terms and conditions stated Page 2 of this agreement and I/we hereby confirm the transfer of all copyrights in and relating to the above-named manuscript, in all forms and media, now or hereafter known, to the International Journal of Drug Regulatory affairs, effective from the date stated below. I/we acknowledge that the IJDRA is relying on this agreement in publishing the above-named manuscript. However, this agreement will be null and void if the manuscript is not published in the IJDRA.
Download link for COPYRIGHT FORM
